{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:44:08Z","timestamp":1792539848602,"version":"4.5.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg\/m2 intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg\/m2 for \u2264 12 cycles. The primary endpoint was overall response rate (\u2265 partial response). Secondary endpoints included clinical benefit response rate (\u2265 minimal response), duration of response, progression-free survival, overall survival, and safety. A total of 266 patients were evaluable for safety, 257 for efficacy; 95% were refractory to their last therapy; 80% were refractory or intolerant to both bortezomib and lenalidomide. Patients had median of 5 prior lines of therapy, including bortezomib, lenalidomide, and thalidomide. Overall response rate was 23.7% with median duration of response of 7.8 months. Median overall survival was 15.6 months. Adverse events (AEs) were manageable without cumulative toxicities. Common AEs were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%). Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2. Thirty-three patients (12.4%) withdrew because of an AE. Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit. This trial was registered at www.clinicaltrials.gov as #NCT00511238.<\/jats:p>","DOI":"10.1182\/blood-2012-05-425934","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T03:12:51Z","timestamp":1343272371000},"page":"2817-2825","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":566,"title":["A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma"],"prefix":"10.1182","volume":"120","author":[{"given":"David S.","family":"Siegel","sequence":"first","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California at San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"University of Toronto Princess Margaret Hospital, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[{"name":"University of Toronto Princess Margaret Hospital, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, AB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic J.","family":"Reu","sequence":"additional","affiliation":[{"name":"Taussig Cancer Center-Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Somlo","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, BC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Stadtmauer","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Abramson Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Kunkel","sequence":"additional","affiliation":[{"name":"Independent Consultant, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Wear","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Consortium, Norwalk, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin F.","family":"Wong","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals Inc, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111811091550900_B1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2019111811091550900_B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment\u2019 approaches in the era of novel agents.","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111811091550900_B3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cncr.24760","article-title":"Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates.","volume":"116","author":"Edwards","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2019111811091550900_B4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3816\/CLML.2010.n.068","article-title":"Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.","volume":"10","author":"Offidani","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2019111811091550900_B5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2019111811091550900_B6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ctrv.2010.08.008","article-title":"Treatment of relapsed and refractory multiple myeloma in the era of novel agents.","volume":"37","author":"van de Donk","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"2019111811091550900_B7","first-page":"22","article-title":"Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.","volume":"24","author":"Richardson","year":"2010","journal-title":"Oncology (Williston Park)"},{"issue":"14","key":"2019111811091550900_B8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2010.34.0760","article-title":"Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.","volume":"29","author":"Mitsiades","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111811091550900_B9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.mam.2009.04.001","article-title":"The proteasomal system.","volume":"30","author":"Jung","year":"2009","journal-title":"Mol Aspects Med"},{"issue":"1","key":"2019111811091550900_B10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s001090050081","article-title":"The ubiquitin-mediated proteolytic pathway as a therapeutic area.","volume":"75","author":"Rolfe","year":"1997","journal-title":"J Mol Med"},{"issue":"1","key":"2019111811091550900_B11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: from the lysosome to ubiquitin and the proteasome.","volume":"6","author":"Ciechanover","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2019111811091550900_B12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cr.2009.137","article-title":"The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives.","volume":"20","author":"Wan","year":"2010","journal-title":"Cell Res"},{"issue":"11","key":"2019111811091550900_B13","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/sj.onc.1207373","article-title":"Regulation of apoptosis proteins in cancer cells by ubiquitin.","volume":"23","author":"Zhang","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"2019111811091550900_B14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"issue":"10","key":"2019111811091550900_B15","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2019111811091550900_B16","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma.","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111811091550900_B17","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"2019111811091550900_B18","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"2019111811091550900_B19","article-title":"Carfilzomib: a selective inhibitor of the chymotrypsin-like activity of the constitutive proteasome and immunoproteasome has anti-tumor activity on multiple myeloma, lymphoma, and leukemia cells with minimal effects on normal cells.","volume":"94","author":"Parlati","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2019111811091550900_B20","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111811091550900_B21","article-title":"The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration [abstract].","volume":"112","author":"Kirk","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111811091550900_B22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp Neurol"},{"issue":"7","key":"2019111811091550900_B23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"issue":"22","key":"2019111811091550900_B24","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2019111811091550900_B25","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2019111811091550900_B26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8504","article-title":"Final results of PX-171-003-A0, part 1 of an open label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract].","volume":"27","author":"Jagannath","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111811091550900_B27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant.","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111811091550900_B28","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2019111811091550900_B29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"issue":"26","key":"2019111811091550900_B30","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111811091550900_B31","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (FACT\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"2019111811091550900_B32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Amer Statist Assn"},{"issue":"4","key":"2019111811091550900_B33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"21","key":"2019111811091550900_B34","article-title":"Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract].","volume":"118","author":"Singhal","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111811091550900_B35","first-page":"126","article-title":"A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and\/or refractory multiple myeloma (R\/R MM) [abstract].","volume":"96","author":"Siegel","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111811091550900_B36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study.","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"2019111811091550900_B37","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111811091550900_B38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma.","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"2019111811091550900_B39","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2019111811091550900_B40","article-title":"A phase I\/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma [abstract].","volume":"30","author":"Mikhael","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111811091550900_B41","article-title":"Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM): a trial of the European Myeloma Network EMN [abstract].","volume":"118","author":"Sonneveld","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111811091550900_B42","article-title":"Multivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomib [abstract].","volume":"118","author":"Squifflet","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111811091550900_B43","article-title":"A phase 1b\/2 study of prolonged infusion carfilzomib in patients with relapsed and\/or refractory (R\/R) multiple myeloma: updated efficacy and tolerability from the completed 20\/56 mg\/m2 expansion cohort of PX-171-007 [abstract].","volume":"118","author":"Papadopoulos","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts"},{"issue":"1","key":"2019111811091550900_B44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"2019111811091550900_B45","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s12032-010-9542-z","article-title":"Management of disease- and treatment-related complications in patients with multiple myeloma.","volume":"27","author":"Gay","year":"2010","journal-title":"Med Oncol"},{"issue":"12","key":"2019111811091550900_B46","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111811091550900_B47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2019111811091550900_B48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"2019111811091550900_B49","article-title":"Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [published online ahead of print June 11, 2012].","author":"Arnulf","journal-title":"Haematologica"},{"issue":"6","key":"2019111811091550900_B50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111811091550900_B51","article-title":"Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract].","volume":"97","author":"Harvey","year":"2012","journal-title":"Haematologica"},{"key":"2019111811091550900_B52","volume-title":"Velcade Prescribing Information","author":"Millennium Pharmaceuticals","year":"2012"},{"key":"2019111811091550900_B53","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s12032-009-9407-5","article-title":"Advances in treatment for relapses and refractory multiple myeloma.","volume":"27","author":"Richards","year":"2010","journal-title":"Med Oncol"},{"key":"2019111811091550900_B54","volume-title":"Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2012","author":"National Comprehensive Cancer Network","year":"2012"},{"key":"2019111811091550900_B55","first-page":"122","article-title":"An update on the phase 1b\/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone (CRd) in patients with relapsed or refractory multiple myeloma [abstract 0295].","volume":"96","author":"Niesvizky","year":"2011","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/14\/2817\/1357318\/zh804012002817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/14\/2817\/1357318\/zh804012002817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T01:30:06Z","timestamp":1642901406000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/14\/2817\/30515\/A-phase-2-study-of-singleagent-carfilzomib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,4]]},"references-count":55,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,10,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-425934","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,4]]}}}